These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 8396395

  • 21. The aging substantia nigra: quantitative histologic study.
    Faraldi F, Reyes MG, Alfieri E, Levi AC.
    Panminerva Med; 1994 Sep; 36(3):103-8. PubMed ID: 7877822
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra?
    Ikemoto K, Nagatsu I, Ito S, King RA, Nishimura A, Nagatsu T.
    Neurosci Lett; 1998 Sep 11; 253(3):198-200. PubMed ID: 9792245
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. SU-E-I-78: Neuromelanin in the Subthalamic Nucleus of Patients with Parkinson's Disease: An Electron Spin Resonance Spectroscopy Study.
    Gomez J, Salmon CG, Filho OB, Santos JP, Pitella J.
    Med Phys; 2012 Jun 11; 39(6Part5):3643. PubMed ID: 28517656
    [Abstract] [Full Text] [Related]

  • 30. Neuromelanin of the human substantia nigra: a mixed-type melanin.
    Odh G, Carstam R, Paulson J, Wittbjer A, Rosengren E, Rorsman H.
    J Neurochem; 1994 May 11; 62(5):2030-6. PubMed ID: 8158151
    [Abstract] [Full Text] [Related]

  • 31. Interaction of human substantia nigra neuromelanin with lipids and peptides.
    Zecca L, Costi P, Mecacci C, Ito S, Terreni M, Sonnino S.
    J Neurochem; 2000 Apr 11; 74(4):1758-65. PubMed ID: 10737635
    [Abstract] [Full Text] [Related]

  • 32. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour.
    Zecca L, Tampellini D, Gerlach M, Riederer P, Fariello RG, Sulzer D.
    Mol Pathol; 2001 Dec 11; 54(6):414-8. PubMed ID: 11724917
    [Abstract] [Full Text] [Related]

  • 33. Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients.
    Lopiano L, Chiesa M, Digilio G, Giraudo S, Bergamasco B, Torre E, Fasano M.
    Biochim Biophys Acta; 2000 Mar 17; 1500(3):306-12. PubMed ID: 10699372
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease.
    Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD.
    J Neurochem; 1989 Jun 17; 52(6):1830-6. PubMed ID: 2723638
    [Abstract] [Full Text] [Related]

  • 36. A critical review of the function of neuromelanin and an attempt to provide a unified theory.
    Nicolaus BJ.
    Med Hypotheses; 2005 Jun 17; 65(4):791-6. PubMed ID: 15949901
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.